146 related articles for article (PubMed ID: 14661992)
1. Emerging therapies for graft-versus-host disease.
Jacobsohn DA
Expert Opin Emerg Drugs; 2003 Nov; 8(2):323-38. PubMed ID: 14661992
[TBL] [Abstract][Full Text] [Related]
2. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.
Jacobsohn DA; Vogelsang GB
Drugs; 2002; 62(6):879-89. PubMed ID: 11929336
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutics for the treatment of graft-versus-host disease.
Jacobsohn DA
Expert Opin Investig Drugs; 2002 Sep; 11(9):1271-80. PubMed ID: 12225248
[TBL] [Abstract][Full Text] [Related]
4. Anti-cytokine therapy for the treatment of graft-versus-host disease.
Jacobsohn DA; Vogelsang GB
Curr Pharm Des; 2004; 10(11):1195-205. PubMed ID: 15078135
[TBL] [Abstract][Full Text] [Related]
5. New developments in the prophylaxis and treatment of graft versus host disease.
Simpson D
Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062
[TBL] [Abstract][Full Text] [Related]
6. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
Basić-Jukić N; Labar B
Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
[TBL] [Abstract][Full Text] [Related]
7. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.
Wolff D; Steiner B; Hildebrandt G; Edinger M; Holler E
Curr Pharm Des; 2009; 15(17):1974-97. PubMed ID: 19519437
[TBL] [Abstract][Full Text] [Related]
9. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Rodriguez V; Anderson PM; Trotz BA; Arndt CA; Allen JA; Khan SP
Pediatr Blood Cancer; 2007 Aug; 49(2):212-5. PubMed ID: 16261610
[TBL] [Abstract][Full Text] [Related]
10. Steroid-refractory graft-vs.-host disease: past, present and future.
Carpenter PA; Sanders JE
Pediatr Transplant; 2003; 7 Suppl 3():19-31. PubMed ID: 12603689
[TBL] [Abstract][Full Text] [Related]
11. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings.
Vogelsang GB; Arai S
Bone Marrow Transplant; 2001 Jun; 27(12):1255-62. PubMed ID: 11548843
[TBL] [Abstract][Full Text] [Related]
13. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
14. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A
Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the treatment of graft-versus-host disease.
Iwasaki T
Clin Med Res; 2004 Nov; 2(4):243-52. PubMed ID: 15931364
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
[TBL] [Abstract][Full Text] [Related]
18. Intestinal graft-versus-host disease: mechanisms and management.
Takatsuka H; Iwasaki T; Okamoto T; Kakishita E
Drugs; 2003; 63(1):1-15. PubMed ID: 12487619
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.
Rager A; Frey N; Goldstein SC; Reshef R; Hexner EO; Loren A; Luger SM; Perl A; Tsai D; Davis J; Vozniak M; Smith J; Stadtmauer EA; Porter DL
Bone Marrow Transplant; 2011 Mar; 46(3):430-5. PubMed ID: 20498647
[TBL] [Abstract][Full Text] [Related]
20. Management of graft-versus-host disease in paediatric bone marrow transplant recipients.
Zecca M; Locatelli F
Paediatr Drugs; 2000; 2(1):29-55. PubMed ID: 10937457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
